Skip to main content

Advertisement

SpringerLink
Log in

Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age–related macular degeneration: real world data from the Fight Retinal Blindness registry

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the outcomes of two different antivascular endothelial growth factor treatment regimens for treatment-naive eyes with neovascular age-related macular degeneration in routine clinical care at 12 and 24 months in Spain.

Methods

Observational study using the Fight Retinal Blindness (FRB) outcomes registry platform. Eyes were treated with fixed bimonthly (FB) aflibercept group at one center and a treat-and-extend (TAE) regimen using either aflibercept or ranibizumab at the other center.

Results

We included 192 eyes. Of these, 160 eyes (83%) completed 12 months (86 TAE and 74 FB) and 79 (41%) completed 24 months (46 for TAE and 33 for FB) of follow-up. No statistically significant differences (p > 0.05) were found regarding mean visual acuity (VA, logMAR letters) at baseline (12 month cohort TAE 59.6 vs FB 57.9; 24 month cohort TAE 61.7 vs FB 62.6), final mean VA (12 month cohort TAE 61.1 vs FB 63.0; 24 month cohort TAE 64.8 vs FB 66.4), and median number of injections (12 months TAE 7 vs FB 7; 24 months TAE 11 vs FB 12). However, the distribution of injection frequencies for the TAE group was larger, with 35% of TAE eyes receiving ≤ 6 injections at 12 months compared with only 19% of FB eyes (p = 0.024).

Conclusion

Similar VA results were observed with TAE and FB regimens, with no differences in the median number of injections. However, the TAE approach seemed to deliver a wider distribution of injection frequencies due to its individualized approach, which may help reduce the burden of injections in some eyes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Data is available upon request to corresponding author.

References

  1. Smith W, Assink J, Klein R et al (2001) Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 108(4):697–704

    Article  CAS  Google Scholar 

  2. Schmidt-Erfurth U, Chong V, Loewenstein A et al (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98(9):1144–1167

    Article  Google Scholar 

  3. Friedman D, O'Colmain B, Muñoz B et al (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122(4):564–572

    Article  Google Scholar 

  4. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431

    Article  CAS  Google Scholar 

  5. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432–1444

    Article  CAS  Google Scholar 

  6. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 121(1):193–201

    Article  Google Scholar 

  7. Fung AE, Lalwani GA, Rosenfeld PJ et al (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143(4):566–583

    Article  CAS  Google Scholar 

  8. Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 119(7):1388–1398

    Article  Google Scholar 

  9. Zarranz-Ventura J, Liew G, Johnston RL et al (2014) The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 121(10):1966–1975

    Article  Google Scholar 

  10. Berg K, Hadzalic E, Gjertsen I et al (2016) Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol. Ophthalmology 123(1):51–59

    Article  Google Scholar 

  11. Silva R, Berta A, Larsen M et al (2018) Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 125(1):57–65

    Article  Google Scholar 

  12. DeCroos FC, Reed D, Adam MK et al (2017) Treat-and-extend therapy using aflibercept for neovascular age-related macular degeneration: a prospective clinical trial. Am J Ophthalmol 180:142–150

    Article  CAS  Google Scholar 

  13. Almuhtaseb H, Kanavati S, Rufai SR et al (2017) One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration. Eye. 31:878–883

    Article  CAS  Google Scholar 

  14. Talks J, Daien V, Finger RP et al (2019) The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol S0039-6257(17):30337–30335

    Google Scholar 

  15. Arnold JJ, Campain A, Barthelmes D et al (2015) Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 122(6):1212–1219

  16. Jaki Mekjavić P, Gregorčič B, Oberč C et al (2018) Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia. BMC Ophthalmol 18(1):333

    Article  Google Scholar 

  17. Vardarinos A, Gupta N, Janjua R et al (2017) 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting. BMC Ophthalmol 17(1):58

    Article  Google Scholar 

  18. Haga A, Kawaji T, Ideta R et al (2018) Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration. Acta Ophthalmol 96(3):e393–e3e8

    Article  CAS  Google Scholar 

  19. Gillies MC, Walton RJ, Arnold JJ et al (2014) Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology. 121(3):676–681

    Article  Google Scholar 

  20. Mehta H, Tufail A, Daien V et al (2018) Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res 65:127–146

    Article  CAS  Google Scholar 

  21. Gillies M, Walton R, Liong J et al (2014) Efficient capture of high-quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! Project. Retina. 34:188–195

    Article  Google Scholar 

  22. Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2(2):e106–e116

    Article  Google Scholar 

  23. Gillies MC, Hunyor AP, Arnold JJ et al (2019) Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol 137(4):372–379

    Article  Google Scholar 

  24. Ohji M, Takahashi K, Okada AA et al (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR. Adv Ther 37(3):1173–1187

    Article  CAS  Google Scholar 

  25. Barthelmes D, Nguyen V, Daien V et al (2018) Two year outcomes of “Treat and Extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina. 38(1):20–28

    Article  CAS  Google Scholar 

  26. Gillies MC, Campain A, Barthelmes D et al (2015) Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 122(9):1837–1845

    Article  Google Scholar 

  27. Guymer RH, Markey CM, McAllister IL et al (2018) Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. 126(5):723–734

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Clínic d’Oftalmologia (ICOF), Hospital Clínic de Barcelona, C/Sabino de Arana 1, 08028, Barcelona, Spain

    Marc Figueras-Roca, Alba Parrado-Carrillo, Ricardo P. Casaroli-Marano, Aina Moll-Udina & Javier Zarranz-Ventura

  2. Biomedical Research Institute August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    Marc Figueras-Roca, Ricardo P. Casaroli-Marano, Aina Moll-Udina & Javier Zarranz-Ventura

  3. Macular Research Group, Save Sight Institute, University of Sydney, Sydney, Australia

    Vuong Nguyen, Mark C. Gillies & Daniel Barthelmes

  4. Department of Ophthalmology, University Hospital Zurich and University of Zurich, Zurich, Switzerland

    Daniel Barthelmes

  5. Department of Surgery, School of Medicine, University of Barcelona, Barcelona, Spain

    Ricardo P. Casaroli-Marano

Authors
  1. Marc Figueras-Roca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alba Parrado-Carrillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vuong Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ricardo P. Casaroli-Marano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aina Moll-Udina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mark C. Gillies
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daniel Barthelmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Javier Zarranz-Ventura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Figueras-Roca.

Ethics declarations

Conflict of interest

MCG and DB are inventors of the software used to collect the data for this analysis. MFR reports personal fees from Allergan outside the submitted work. JZV reports personal fees from Allergan, Bayer, Novartis, and Roche outside the submitted work.

Ethics approval

Institutional review board and ethics committee approvals were obtained from both study sites.

Consent to participate and for publication

All study participants provided written informed consent.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Figueras-Roca, M., Parrado-Carrillo, A., Nguyen, V. et al. Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age–related macular degeneration: real world data from the Fight Retinal Blindness registry. Graefes Arch Clin Exp Ophthalmol 259, 1463–1470 (2021). https://doi.org/10.1007/s00417-020-05016-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-020-05016-9

Keywords

Search

Navigation